Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Build A Bear Workshop Inc (BBW) vs Summit Therapeutics Inc (SMMT) Price & Performance

Build A Bear Workshop IncTrade
Summit Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Build A Bear Workshop Inc vs Summit Therapeutics Inc — how do they compare? Build A Bear Workshop Inc trades at $36.64 (market cap $461.88M), while Summit Therapeutics Inc trades at $15.29 (market cap $12.06B). The key difference: Summit Therapeutics Inc is far larger — about 26.1× Build A Bear Workshop Inc's market cap, and Build A Bear Workshop Inc pays a 2.5% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.

BBWSMMT
Market Cap
$461.88M$12.06B
Sector
Consumer CyclicalHealth
52-Week High
$75.85$26.98
52-Week Low
$29.84$12.55
Enterprise Value
$561.32M$11.39B
Dividend Yield
2.5%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Build A Bear Workshop Inc

Build-A-Bear Workshop (BBW) trades at $36.09, down 3.14% today, but maintains strong fundamentals with a P/E of 8.63 and robust profitability metrics including 35.87% ROE. The stock shows technical bullish signals with moving averages supporting upward momentum, though RSI levels suggest potential near-term overbought conditions. Recent earnings beats and strategic product launches position the company for continued growth despite current price weakness.

BBW presents compelling value with analyst consensus price target of $62.50 representing 73% upside potential. The debt-free balance sheet, consistent dividend payments, and international expansion strategy support long-term growth, though near-term consumer spending pressures and competitive retail environment pose execution risks for investors.

Summit Therapeutics Inc

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.

Returns comparison

Trailing returns across standard periods

About Build A Bear Workshop Inc

Build-A-Bear is a global retailer specializing in customizable stuffed animals. It offers an interactive make-your-own experience where customers choose, stuff, and dress their furry friends in-store or online.

Read more on BBW

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Read more on SMMT